Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database-Reference-Cited by-同舟云学术

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database

Published:2022-08-31 Issue:4 Volume:3 Page:1252-1261
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

McCurdy Arleigh¹,Louzada Martha²,Venner Christopher P.³,Visram Alissa¹,Masih‐Khan Esther⁴⁵^ORCID,Kardjadj Moustafa⁵,Jimenez‐Zepeda Victor H.⁶,LeBlanc Richard⁷,Sebag Michael⁸,Song Kevin⁹,White Darrell¹⁰,Mian Hira¹¹^ORCID,Stakiw Julie¹²,Reiman Anthony¹³^ORCID,Aslam Muhammad¹⁴,Kotb Rami¹⁵,Gul Engin⁵,Reece Donna⁴⁵

Affiliation:

1. The Ottawa Hospital Ottawa Ontario Canada

2. London Regional Cancer Center London Ontario Canada

3. Cross Cancer Institute University of Alberta Edmonton Alberta Canada

4. Princess Margaret Cancer Centre Toronto Ontario Canada

5. Canadian Myeloma Research Group Vaughan Ontario Canada

6. Arnie Charbonneau Cancer Institute University of Calgary Calgary Alberta Canada

7. Maisonneuve‐Rosemont Hospital Research Centre University of Montreal Montreal Quebec Canada

8. McGill University Montreal Quebec Canada

9. BC Cancer Agency Vancouver General Hospital Vancouver British Columbia Canada

10. Queen Elizabeth II Health Sciences Centre Dalhousie University Halifax Nova Scotia Canada

11. Juravinski Cancer Center Hamilton Ontario Canada

12. Saskatoon Cancer Centre University of Saskatchewan Saskatoon Saskatchewan Canada

13. Saint John Regional Hospital Saint John New Brunswick Canada

14. Allan Blair Cancer Centre Regina Saskatchewan Canada

15. Cancer Care Manitoba Winnipeg Manitoba Canada

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.559

Reference33 articles.

1. Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of castor;Spencer A;Blood.,2017

2. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

3. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

4. Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study;eJHaem;2024-07-23